9.51
price down icon2.36%   -0.23
after-market After Hours: 9.51
loading
Urogen Pharma Ltd stock is traded at $9.51, with a volume of 406.78K. It is down -2.36% in the last 24 hours and down -7.13% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$9.74
Open:
$9.77
24h Volume:
406.78K
Relative Volume:
1.09
Market Cap:
$401.32M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-2.5913
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-9.94%
1M Performance:
-7.13%
6M Performance:
-32.84%
1Y Performance:
-44.35%
1-Day Range:
Value
$9.29
$9.81
1-Week Range:
Value
$9.29
$11.09
52-Week Range:
Value
$9.29
$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Name
Urogen Pharma Ltd
Name
Phone
972 9 770 7601
Name
Address
9 HA'TA'ASIYA ST, RA'ANANA
Name
Employee
217
Name
Twitter
@UroGenPharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
URGN's Discussions on Twitter

Compare URGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
URGN
Urogen Pharma Ltd
9.51 401.32M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
480.35 123.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
723.47 79.09B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.94 37.97B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.20 31.74B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.70 27.71B 3.32B -860.46M -1.04B -8.32

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-19-25 Resumed Ladenburg Thalmann Buy
Aug-22-24 Initiated Guggenheim Buy
Feb-08-23 Downgrade Jefferies Buy → Hold
Apr-27-22 Initiated Berenberg Buy
Apr-16-20 Reiterated H.C. Wainwright Buy
Apr-13-20 Reiterated H.C. Wainwright Buy
Jan-09-20 Initiated National Securities Neutral
May-30-19 Initiated JP Morgan Neutral
May-29-19 Initiated Goldman Neutral
Jan-29-19 Initiated H.C. Wainwright Buy
Nov-08-18 Resumed Jefferies Buy
Apr-04-18 Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18 Initiated Ladenburg Thalmann Buy
Nov-15-17 Reiterated Oppenheimer Outperform
Nov-15-17 Downgrade Raymond James Outperform → Mkt Perform
View All

Urogen Pharma Ltd Stock (URGN) Latest News

pulisher
12:30 PM

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

12:30 PM
pulisher
08:33 AM

UroGen stock holds Buy rating, $64 target from H.C. Wainwright By Investing.com - Investing.com South Africa

08:33 AM
pulisher
Feb 24, 2025

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - BioSpace

Feb 24, 2025
pulisher
Feb 24, 2025

Can UroGen's Next Move Transform Urothelial Cancer Treatment? Key Insights Coming at TD Cowen - StockTitan

Feb 24, 2025
pulisher
Feb 21, 2025

UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen Plots Expansion, Brings In A New Asset - News & Insights

Feb 20, 2025
pulisher
Feb 20, 2025

Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen acquires oncolytic virus, expands cancer treatment options By Investing.com - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio -February 20, 2025 at 10:58 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen acquires oncolytic virus, expands cancer treatment options - Investing.com India

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Where are the Opportunities in (URGN) - Stock Traders Daily

Feb 20, 2025
pulisher
Feb 19, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World

Feb 19, 2025
pulisher
Feb 19, 2025

UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Feb 19, 2025
pulisher
Feb 14, 2025

UroGen Announces Results from Subgroup Analyses of the Pivotal E - WICZ

Feb 14, 2025
pulisher
Feb 14, 2025

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire

Feb 14, 2025
pulisher
Feb 14, 2025

D. Boral Capital Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN) - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

UroGen Pharma Ltd. Announces Results from A Long-Term Follow-Up Study with JELMYTO for Primary Treatment of Low-Grade, Upper Tract Urothelial Cancer in Adult Patients - Marketscreener.com

Feb 13, 2025
pulisher
Feb 12, 2025

JELMYTO shows long-term effectiveness in cancer study By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 12, 2025

JELMYTO shows long-term effectiveness in cancer study - Investing.com India

Feb 12, 2025
pulisher
Feb 12, 2025

Data From A Long-Term Follow-Up Study To The Olympus Trial Published In The Journal Of Urology - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet - Simply Wall St

Feb 12, 2025
pulisher
Feb 11, 2025

Urogen Pharma's general counsel sells $82,202 in shares - MSN

Feb 11, 2025
pulisher
Feb 09, 2025

(URGN) Trading Advice - Stock Traders Daily

Feb 09, 2025
pulisher
Feb 08, 2025

Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells 7,379 Shares of Stock - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Has $216,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Feb 08, 2025
pulisher
Feb 08, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells $82,202.06 in Stock - Armenian Reporter

Feb 07, 2025
pulisher
Feb 05, 2025

UroGen Pharma's chief medical officer sells shares worth $50,698 - MSN

Feb 05, 2025
pulisher
Feb 04, 2025

UroGen Pharma's chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Canada

Feb 04, 2025
pulisher
Feb 04, 2025

UroGen Pharma’s chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Nigeria

Feb 04, 2025
pulisher
Feb 04, 2025

Urogen Pharma's general counsel sells $82,202 in shares By Investing.com - Investing.com South Africa

Feb 04, 2025
pulisher
Feb 03, 2025

URGN (UroGen Pharma) Revenue per Share : $2.39 (TTM As of Sep. 2024) - GuruFocus.com

Feb 03, 2025
pulisher
Feb 02, 2025

URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Feb 02, 2025
pulisher
Feb 01, 2025

URGN (UroGen Pharma) EPS without NRI : $-2.60 (TTM As of Sep. 2024) - GuruFocus.com

Feb 01, 2025
pulisher
Jan 31, 2025

UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha

Jan 31, 2025
pulisher
Jan 30, 2025

UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian

Jan 30, 2025
pulisher
Jan 26, 2025

JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

JPMorgan Chase & Co. Grows Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Jan 26, 2025
pulisher
Jan 26, 2025

UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts - MarketBeat

Jan 25, 2025

Urogen Pharma Ltd Stock (URGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.40
price up icon 0.53%
$22.96
price up icon 2.04%
$33.69
price down icon 0.33%
$357.50
price down icon 0.20%
$110.97
price down icon 5.14%
biotechnology ONC
$259.70
price up icon 0.47%
Cap:     |  Volume (24h):